Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cevostamab Monotherapy and Combination Therapy in Relapsed or Refractory Multiple Myeloma
NCT04910568Phase 1Recruiting
- Sponsor
- Genentech
- Start
- Jul 2021
- Primary completion
- Dec 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 1, randomised, open-label trial of cevostamab in multiple myeloma (MM) (3 arms), sponsored by Genentech. Primary endpoints: Recommended Phase II Dose, Percentage of Participants with Adverse Events and 4 more. Started Jul 2021; status: recruiting.
02
Drugs
cevostamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04910568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04910568.